| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DC2 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-149aa |
| 氨基酸序列 | METLYRVPFLVLECPNLKLKKPPWLHMPSAMTVYALVVVSYFLITGGIIYDVIVEPPSVGSMTDEHGHQRPVAFLAYRVNGQYIMEGLASSFLFTMGGLGFIILDRSNAPNIPKLNRFLLLFIGFVCVLLSFFMARVFMRMKLPGYLMG |
| 分子量 | 43.2 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于重组人DC2蛋白的示例文献(模拟摘要，非真实文献)：
---
1. **文献名称**: *Expression and functional characterization of recombinant human DC2 in modulating T-cell responses*
**作者**: Chen L, et al.
**摘要**: 该研究成功在大肠杆菌中表达并纯化了重组人DC2蛋白，验证其通过激活MAPK信号通路促进Th2细胞分化，证明其在免疫调节中的作用。
2. **文献名称**: *Structural insights into human DC2 glycoprotein and its interaction with TLR4*
**作者**: Watanabe K, et al.
**摘要**: 通过X射线晶体学解析DC2蛋白结构，发现其C端结构域与TLR4结合，揭示其在先天免疫中作为病原体识别受体的分子机制。
3. **文献名称**: *Recombinant DC2 as a therapeutic target in autoimmune encephalomyelitis*
**作者**: Müller R, et al.
**摘要**: 动物实验表明，重组DC2蛋白抑制炎性细胞因子IL-6/IL-23分泌，显著减轻实验性自身免疫性脑脊髓炎(EAE)模型症状。
---
实际文献需通过PubMed或Web of Science检索关键词“recombinant human DC2 protein”获取。如需特定研究方向(如表达、结构或疾病应用)，可进一步调整检索策略。
Recombinant human DC2 protein (DCLK1) is a microtubule-associated kinase encoded by the *DCLK1* gene, belonging to the doublecortin (DCX) family. It contains an N-terminal doublecortin domain for microtubule binding and a C-terminal serine/threonine kinase domain, enabling dual roles in cytoskeletal regulation and signal transduction. Initially studied for its neural functions, DC2 is critical in neurogenesis, neuronal migration, and axonal guidance during brain development. However, recent research highlights its oncogenic potential, particularly as a marker of cancer stem cells (CSCs) in gastrointestinal, pancreatic, and colorectal cancers. DC2 overexpression correlates with tumor progression, metastasis, and therapy resistance by promoting epithelial-mesenchymal transition (EMT) and sustaining stemness.
Recombinant DC2 is produced using expression systems (e.g., *E. coli* or mammalian cells) to study its structure-function relationships. Its kinase activity and interactions with microtubules or signaling pathways (e.g., Notch, Wnt/β-catenin) make it a therapeutic target. Inhibitors targeting the DC2 kinase domain are under investigation to disrupt CSC-driven malignancies. Additionally, recombinant DC2 serves as a tool for antibody development, biomarker validation, and high-throughput drug screening. Despite progress, its isoform diversity, splice variants, and context-dependent roles in normal vs. pathological conditions require further exploration to advance translational applications.
×
